Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
Cost analysis
Cost per response
Hepatorenal syndrome
Hepatorenal syndrome reversal
Terlipressin
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
02
07
2023
accepted:
31
08
2023
medline:
30
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Hepatorenal syndrome (HRS), a special form of acute kidney failure, is a rare, acute, life-threatening complication of cirrhosis and has a very poor prognosis. Terlipressin (TERLIVAZ A decision analytic model was developed to estimate the HRS treatment-related cost per response over an HRS hospitalization (assuming 14 days). Patients can experience either HRS reversal (complete response) or no HRS reversal (partial/no response) upon receipt of treatment. The efficacy, safety, and treatment duration data were from published head-to-head randomized international trials. Total treatment cost comprised drug acquisition and treatment-related costs (intensive care unit [ICU], dialysis [intermittent or continuous], pulse oximetry monitoring for terlipressin, and adverse events) sourced from the published literature. Cost per response, defined as the total treatment cost per HRS reversal was estimated for each treatment. The number needed to treat (NNT), defined as the number of patients treated to achieve HRS reversal in 1 additional patient, was estimated. Cost per response of terlipressin + albumin was lower than midodrine and octreotide + albumin (M&O) (US$85,315 vs. $467,794) and norepinephrine + albumin ($81,614 vs. $139,324). NNT for HRS reversal was 2 patients with terlipressin + albumin vs. M&O + albumin and 4 patients with terlipressin + albumin vs. norepinephrine + albumin, respectively. The analysis shows that terlipressin is a cost-effective treatment due to its higher efficacy and administration in the non-ICU setting. Terlipressin is a value-based treatment option for appropriate adults with HRS with rapid reduction in kidney function. Hepatorenal syndrome, a functional, progressive kidney failure, is a life-threatening complication of cirrhosis. It is important to improve kidney function in patients who are hospitalized with hepatorenal syndrome considering the cost of treatment. This study assessed the cost per complete response/ hepatorenal syndrome reversal of terlipressin + albumin from a United States hospital perspective. This study shows that terlipressin improves kidney function with lower intensive care unit and dialysis costs compared with unapproved treatments. Terlipressin is a cost-effective, value-based treatment option for appropriate adults with hepatorenal syndrome with rapid reduction in kidney function.
Autres résumés
Type: plain-language-summary
(eng)
Hepatorenal syndrome, a functional, progressive kidney failure, is a life-threatening complication of cirrhosis. It is important to improve kidney function in patients who are hospitalized with hepatorenal syndrome considering the cost of treatment. This study assessed the cost per complete response/ hepatorenal syndrome reversal of terlipressin + albumin from a United States hospital perspective. This study shows that terlipressin improves kidney function with lower intensive care unit and dialysis costs compared with unapproved treatments. Terlipressin is a cost-effective, value-based treatment option for appropriate adults with hepatorenal syndrome with rapid reduction in kidney function.
Identifiants
pubmed: 37812332
doi: 10.1007/s12325-023-02674-z
pii: 10.1007/s12325-023-02674-z
pmc: PMC10611877
doi:
Substances chimiques
Terlipressin
7Z5X49W53P
Vasoconstrictor Agents
0
terlivaz
0
Norepinephrine
X4W3ENH1CV
Albumins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5432-5446Informations de copyright
© 2023. The Author(s).
Références
Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. A review of hepatorenal syndrome. Cureus. 2021;13(7): e16084.
pubmed: 34367745
pmcid: 8330394
Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ. 2019;22(5):421–9.
doi: 10.1080/13696998.2019.1580201
pubmed: 30724682
Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579-1589e1572.
doi: 10.1053/j.gastro.2016.02.026
pubmed: 26896734
Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal syndrome: a review of pathophysiology and current treatment options. Semin Intervent Radiol. 2015;32(4):445–54.
doi: 10.1055/s-0035-1564794
pubmed: 26622108
pmcid: 4640915
Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J. 2008;84(998):662–70.
doi: 10.1136/gut.2006.107789
pubmed: 19201943
Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Netw Open. 2020;3(4): e201997.
doi: 10.1001/jamanetworkopen.2020.1997
pubmed: 32239220
pmcid: 7118516
Pant C, Jani BS, Desai M, et al. Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002–2012. J Investig Med. 2016;64(1):33–8.
doi: 10.1136/jim-d-15-00181
pubmed: 26755811
American Hospital Association. Archived: Fast facts on U.S. hospitals. https://www.aha.org/statistics/2020-01-07-archived-fast-facts-us-hospitals-2019 . Published 2019. Accessed 12 Jan 2022.
Flamm SL, Brown K, Wadei HM, et al. The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin. Liver Transpl. 2021;27(8):1191–202.
doi: 10.1002/lt.26072
pubmed: 33848394
pmcid: 8457138
Jamil K, Huang X, Hayashida D, Lodaya K. The hepatorenal syndrome patient pathway: retrospective analysis of electronic health records. Curr Ther Res Clin Exp. 2022;96: 100663.
doi: 10.1016/j.curtheres.2022.100663
pubmed: 35399809
pmcid: 8987804
Do A, Ezaz G. Increasing incidence and cost, but decreasing mortality in patients with hepatorenal syndrome: a study of the National Inpatient Sample 2005–2001. Hepatology. 2015;62(Abstract 283):345A–362A.
Rice JB, White AG, Galebach P, et al. The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States. Curr Med Res Opin. 2017;33(8):1473–80.
doi: 10.1080/03007995.2017.1331211
pubmed: 28509578
Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017;9(6):293–9.
doi: 10.4254/wjh.v9.i6.293
pubmed: 28293378
pmcid: 5332418
Fukazawa K, Lee HT. Updates on hepatorenal syndrome. J Anesth Clin Res. 2013;4(9):352.
pubmed: 24459604
pmcid: 3897161
Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002;35(5):1179–85.
doi: 10.1053/jhep.2002.33160
pubmed: 11981768
Glass L, Sharma P. Evidence-based therapeutic options for hepatorenal syndrome. Gastroenterology. 2016;150(4):1031–3.
doi: 10.1053/j.gastro.2016.02.050
pubmed: 26922867
Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40(1):140–6.
doi: 10.1016/j.jhep.2003.09.019
pubmed: 14672625
Dundar HZ, Yilmazlar T. Management of hepatorenal syndrome. World J Nephrol. 2015;4(2):277–86.
doi: 10.5527/wjn.v4.i2.277
pubmed: 25949942
pmcid: 4419138
Mallinckrodt Pharmaceuticals. TERLIVAZ
Bajaj JS, O’Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022;117(2):225–52.
doi: 10.14309/ajg.0000000000001595
pubmed: 35006099
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the american association for the study of liver diseases. Hepatology. 2021;74(2):1014–48.
doi: 10.1002/hep.31884
pubmed: 33942342
European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.
doi: 10.1016/j.jhep.2018.03.024
O’Leary JG, Levitsky J, Wong F, Nadim MK, Charlton M, Kim WR. Protecting the kidney in liver transplant candidates: Practice-Based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16(9):2516–31.
doi: 10.1111/ajt.13790
pubmed: 26990924
Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver disease. J Gastroenterol Hepatol. 2018;33(3):591–8.
doi: 10.1111/jgh.14009
pubmed: 28981166
Jamil K, Pappas SC, Devarakonda KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2. J Exp Pharmacol. 2018;10:1–7.
doi: 10.2147/JEP.S146034
pubmed: 29302194
Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol. 2011;26(Suppl 1):109–14.
doi: 10.1111/j.1440-1746.2010.06583.x
pubmed: 21199521
Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360–8.
doi: 10.1053/j.gastro.2008.02.014
pubmed: 18471513
Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–28.
doi: 10.1056/NEJMoa2008290
pubmed: 33657294
Karvellas CJ, Subramanian R, Olson JC, Jamil K. Role of terlipressin in patients with hepatorenal syndrome-acute kidney injury admitted to the ICU: a substudy of the CONFIRM Trial. Crit Care Explor. 2023;5(4): e0890.
doi: 10.1097/CCE.0000000000000890
pubmed: 37007903
pmcid: 10060094
Morgenstern J. Peripheral vasopressors: the myth and the evidence. https://first10em.com/peripheralperssors/ . Published 2018. Accessed 26 Sep 2022.
Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–8.
doi: 10.1016/j.jhep.2012.01.012
pubmed: 22322237
Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62(2):567–74.
doi: 10.1002/hep.27709
pubmed: 25644760
Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study. Indian J Gastroenterol. 2018;37(5):424–9.
doi: 10.1007/s12664-018-0876-3
pubmed: 30178092
Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71(2):600–10.
doi: 10.1002/hep.30208
pubmed: 30076614
Nayyar S, Kaur R, Mohan G, Chandey M. A prospective study to compare the efficacy of noradrenaline verses terlipressin in hepatorenal syndrome in patients with advanced cirrhosis. Int J Adv Med. 2021;8(9):1312–8.
doi: 10.18203/2349-3933.ijam20213215
International Business Machines. Micromedex
Jung CY, Chang JW. Hepatorenal syndrome: current concepts and future perspectives. Clin Mol Hepatol. 2023. https://doi.org/10.3350/cmh.2023.0024 .
Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol. 2022;15:17562848221102680.
doi: 10.1177/17562848221102679
pubmed: 35721838
pmcid: 9201357
United States Bureau of Labor Statistics. Consumer Price Index - Medical Care. https://www.bls.gov/cpi/data.htm . Published 2022. Accessed 15 Sep 2022.
Hospital obstruction: Reduced throughput and increased cost associated with discharge from step‐down units [Abstract 178]. Paper presented at: Hospital Medicine (J Hosp Med); March 24-27, 2014; Las Vegas, Nevada, USA
Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA, Investigators BK. Cost of acute renal replacement therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study. Crit Care. 2010;14(2):R46.
doi: 10.1186/cc8933
pubmed: 20346163
pmcid: 2887158
Mattos AZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol. 2016;28(3):345–51.
doi: 10.1097/MEG.0000000000000537
pubmed: 26649801
Ferreira LM, Terrabuio DR, Ferreira CM, Mazo DFC, Haddad LBP. Cost effectiveness of using terlipressin to treat hepatorenal syndrome. Arq Gastroenterol. 2022;59(2):268–74.
doi: 10.1590/s0004-2803.202202000-48
pubmed: 35830040
Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81.
doi: 10.1056/NEJMp1011024
pubmed: 21142528